Small vesicles, big potential: A review of innovative exosome delivery and molecular mechanisms in preclinical myocardial infarction models

Abstract

Exosomes have emerged as promising therapeutic carriers, with over 40 000 scientific publications reflecting their exponential growth in biomedical research. Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide. Among these, myocardial infarction (MI) represents the most prevalent and devastating form, contributing significantly to global morbidity and mortality. Reducing the mortality and long-term complications associated with MI is therefore both necessary and urgent. Exosomes, naturally occurring extracellular vesicles, offer a promising cell-free alternative for drug delivery and cardiac repair and regeneration after ischemic injury due to their ability to transport bioactive proteins, lipids, and RNA. This narrative review summarizes recent advancements in exosome-based therapeutics for ischemic heart disease, focusing on the efficacy of various animal models. Various approaches are being studied to optimize exosome-based therapies, including methods to enhance their stability, targeting ability, and bioavailability in the cardiovascular system, highlighting the potential of exosomes not only as drug delivery vehicles but also as regenerative mediators capable of promoting myocardial repair and reducing MI. With continued advances in exosome technology and a deeper understanding of their biological functions, there is growing optimism that these vesicles could pave the way for more effective and less invasive treatments for cardiovascular diseases in the near future.

Keywords

animal models / drug delivery / exosome / extracellular vesicle / myocardial infarction

References

[1] WHO. Cardiovascular diseases (CVDs). Accessed December 31, 2024. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

[2] Celermajer DS, Chow CK, Marijon E, Anstey NM, Woo KS. Cardiovascular disease in the developing world: prevalences, patterns, and the potential of early disease detection. J Am Coll Cardiol. 2012; 60(14): 1207-1216.

[3] Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020; 76(25): 2982-3021.

[4] Carrabba M, Madeddu P. Current strategies for the manufacture of small size tissue engineering vascular grafts. Front Bioeng Biotechnol. 2018; 6:41.

[5] Han J, Trumble DR. Cardiac assist devices: early concepts, current technologies, and future innovations. Bioengineering (Basel). 2019; 6(1): 18.

[6] Fatullayev J, Samak M, Sabashnikov A, et al. Non-heart-beating donor heart transplantation: breaking the taboo. Med Sci Monit Basic Res. 2015; 21: 153-156.

[7] Uddin MJ, Mohite P, Munde S, et al. Extracellular vesicles: the future of therapeutics and drug delivery systems. Intell Pharm. 2024; 2(3): 312-328.

[8] Reiss AB, Ahmed S, Johnson M, Saeedullah U, De Leon J. Exosomes in cardiovascular disease: from mechanism to therapeutic target. Metabolites. 2023; 13(4):479.

[9] Tenchov R, Sasso JM, Wang X, Liaw WS, Chen CA, Zhou QA. Exosomes horizontal line nature's lipid nanoparticles, a rising star in drug delivery and diagnostics. ACS Nano. 2022; 16(11): 17802-17846.

[10] Barré-Sinoussi F, Montagutelli X. Animal models are essential to biological research: issues and perspectives. Future Sci OA. 2015; 1(4):Fso63.

[11] Gould SJ, Raposo G. As we wait: coping with an imperfect nomenclature for extracellular vesicles. J Extracell Vesicles. 2013; 2: 10.

[12] Loyer X, Vion AC, Tedgui A, Boulanger CM. Microvesicles as cell-cell messengers in cardiovascular diseases. Circ Res. 2014; 114(2): 345-353.

[13] Oggero S, Austin-Williams S, Norling LV. The contrasting role of extracellular vesicles in vascular inflammation and tissue repair. Front Pharmacol. 2019; 10:1479.

[14] Mirnikjoo B, Balasubramanian K, Schroit AJ. Suicidal membrane repair regulates phosphatidylserine externalization during apoptosis. J Biol Chem. 2009; 284(34): 22512-22516.

[15] Ibrahim A, Marban E. Exosomes: fundamental biology and roles in cardiovascular physiology. Annu Rev Physiol. 2016; 78: 67-83.

[16] Minciacchi VR, Freeman MR, Di Vizio D. Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomes. Semin Cell Dev Biol. 2015; 40: 41-51.

[17] Gurung S, Perocheau D, Touramanidou L, Baruteau J. The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun Signal. 2021; 19(1):47.

[18] Perrin P, Janssen L, Janssen H, et al. Retrofusion of intralumenal MVB membranes parallels viral infection and coexists with exosome release. Curr Biol. 2021; 31(17): 3884-3893.e4.

[19] Mir B, Goettsch C. Extracellular vesicles as delivery vehicles of specific cellular cargo. Cells. 2020; 9(7):1601.

[20] Yellon DM, Davidson SM. Exosomes: nanoparticles involved in cardioprotection? Circ Res. 2014; 114(2): 325-332.

[21] Coughlan C, Bruce KD, Burgy O, et al. Exosome isolation by ultracentrifugation and precipitation and techniques for downstream analyses. Curr Protoc Cell Biol. 2020; 88(1):e110.

[22] Ji Z, Wang C. Mesenchymal stem cell-derived exosomal mir-21-5p inhibits YAP1 expression and improves outcomes in myocardial infarction. BMC Cardiovasc Disord. 2024; 24(1):547.

[23] Gollmann-Tepeköylü C, Pölzl L, Graber M, et al. miR-19a-3p containing exosomes improve function of ischaemic myocardium upon shock wave therapy. Cardiovasc Res. 2020; 116(6): 1226-1236.

[24] Monguio-Tortajada M, Galvez-Monton C, Bayes-Genis A, Roura S, Borras FE. Extracellular vesicle isolation methods: rising impact of size-exclusion chromatography. Cell Mol Life Sci. 2019; 76(12): 2369-2382.

[25] Li J, Sun S, Zhu D, et al. Inhalable stem cell exosomes promote heart repair after myocardial infarction. Circulation. 2024; 150(9): 710-723.

[26] Marzouk RM, Gab-Allah MA, Kim J. Polyethylene glycol (PEG)-based precipitation for exosome enrichment: a review on recent developments, current challenges, and future perspectives. Korea Sci. 2025; 38(2): 42-64.

[27] Santoso MR, Ikeda G, Tada Y, et al. Exosomes from induced pluripotent stem cell-derived cardiomyocytes promote autophagy for myocardial repair. J Am Heart Assoc. 2020; 9(6):e014345.

[28] Lobb RJ, Becker M, Wen SW, et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracell Vesicles. 2015; 4:27031.

[29] Yuan J, Yang H, Liu C, et al. Microneedle patch loaded with exosomes containing microRNA-29b prevents cardiac fibrosis after myocardial infarction. Adv Healthc Mater. 2023; 12(13):e2202959.

[30] Chung JJ, Kim ST, Zaman S, et al. Therapeutic efficacy of cryopreserved, allogeneic extracellular vesicles for treatment of acute myocardial infarction. Int Heart J. 2021; 62(2): 381-389.

[31] Chen Y, Qi W, Wang Z, Niu F. Exosome source matters: a comprehensive review from the perspective of diverse cellular origins. Pharmaceutics. 2025; 17(2):147.

[32] Liang B, He X, Zhao YX, Zhang XX, Gu N. Advances in exosomes derived from different cell sources and cardiovascular diseases. Biomed Res Int. 2020; 2020:7298687.

[33] Nail HM, Chiu CC, Leung CH, Ahmed MMM, Wang HD. Exosomal miRNA-mediated intercellular communications and immunomodulatory effects in tumor microenvironments. J Biomed Sci. 2023; 30(1):69.

[34] Rayat Pisheh H, Sani M. Mesenchymal stem cells derived exosomes: a new era in cardiac regeneration. Stem Cell Res Ther. 2025; 16(1): 16.

[35] Xiao C, Wang K, Xu Y, et al. Transplanted mesenchymal stem cells reduce autophagic flux in infarcted hearts via the exosomal transfer of miR-125b. Circ Res. 2018; 123(5): 564-578.

[36] Peng Y, Zhao JL, Peng ZY, Xu WF, Yu GL. Exosomal miR-25-3p from mesenchymal stem cells alleviates myocardial infarction by targeting pro-apoptotic proteins and EZH2. Cell Death Dis. 2020; 11(5):317.

[37] Clifford DM, Fisher SA, Brunskill SJ, et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev. 2012;(2):CD006536.

[38] Fisher SA, Zhang H, Doree C, Mathur A, Martin-Rendon E. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev. 2015; 9:CD006536.

[39] Belien H, Evens L, Hendrikx M, Bito V, Bronckaers A. Combining stem cells in myocardial infarction: the road to superior repair? Med Res Rev. 2022; 42(1): 343-373.

[40] Miao C, Lei M, Hu W, Han S, Wang Q. A brief review: the therapeutic potential of bone marrow mesenchymal stem cells in myocardial infarction. Stem Cell Res Ther. 2017; 8(1):242.

[41] Barile L, Moccetti T, Marban E, Vassalli G. Roles of exosomes in cardioprotection. Eur Heart J. 2017; 38(18): 1372-1379.

[42] Li T, Gu J, Yang O, Wang J, Wang Y, Kong J. Bone marrow mesenchymal stem cell-derived exosomal miRNA-29c decreases cardiac ischemia/reperfusion injury through inhibition of excessive autophagy via the PTEN/Akt/mTOR signaling pathway. Circ J. 2020; 84(8): 1304-1311.

[43] Wang C, Zhang C, Liu L, et al. Macrophage-derived mir-155-containing exosomes suppress fibroblast proliferation and promote fibroblast inflammation during cardiac injury. Mol Ther. 2017; 25(1): 192-204.

[44] Qi L, Luo DZ, Li H, Yan J, He W. Macrophage-driven exosomes regulate the progression of cardiovascular disease. Front Pharmacol. 2025; 16:1563800.

[45] McDonald MK, Tian Y, Qureshi RA, et al. Functional significance of macrophage-derived exosomes in inflammation and pain. Pain. 2014; 155(8): 1527-1539.

[46] Depeille P, Henricks LM, van de Ven RA, et al. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth. Nat Cell Biol. 2015; 17(6): 804-815.

[47] Dai Y, Wang S, Chang S, et al. M2 macrophage-derived exosomes carry microRNA-148a to alleviate myocardial ischemia/reperfusion injury via inhibiting TXNIP and the TLR4/NF-kappaB/NLRP3 inflammasome signaling pathway. J Mol Cell Cardiol. 2020; 142: 65-79.

[48] Chae CW, Choi G, Yoon T, Kwon YW. Exosome-based therapy in cardiovascular diseases: a new frontier in cardiovascular disease treatment. Korean Circ J. 2025; 55(6): 461-480.

[49] Bernath-Nagy D, Kalinyaprak MS, Giannitsis E, et al. Circulating extracellular vesicles as biomarkers in the diagnosis, prognosis and therapy of cardiovascular diseases. Front Cardiovasc Med. 2024; 11:1425159.

[50] Wang B, Cao C, Han D, et al. Dysregulation of miR-342-3p in plasma exosomes derived from convalescent AMI patients and its consequences on cardiac repair. Biomed Pharmacother. 2021; 142:112056.

[51] Minghua W, Zhijian G, Chahua H, et al. Plasma exosomes induced by remote ischaemic preconditioning attenuate myocardial ischaemia/reperfusion injury by transferring miR-24. Cell Death Dis. 2018; 9(3):320.

[52] Liu Z, Zhu D, Yu F, et al. Exosomal miR-17-3p alleviates programmed necrosis in cardiac ischemia/reperfusion injury by regulating TIMP3 expression. Oxidative Med Cell Longev. 2022; 2022:2785113.

[53] Carrozzo A, Cappucci IP, Basile L, Tremoli E, Zavan B, Ferroni L. Extracellular vesicles in cardiac surgery: unlocking new frontiers in cardioprotection and patient outcomes. Clin Exp Med. 2025; 26(1):36.

[54] Carrozzo A, Casieri V, Di Silvestre D, et al. Plasma exosomes characterization reveals a perioperative protein signature in older patients undergoing different types of on-pump cardiac surgery. Geroscience. 2021; 43(2): 773-789.

[55] Pizzino F, Furini G, Casieri V, et al. Late plasma exosome microRNA-21-5p depicts magnitude of reverse ventricular remodeling after early surgical repair of primary mitral valve regurgitation. Front Cardiovasc Med. 2022; 9:943068.

[56] Jansen F, Nickenig G, Werner N. Extracellular vesicles in cardiovascular disease: potential applications in diagnosis, prognosis, and epidemiology. Circ Res. 2017; 120(10): 1649-1657.

[57] Casieri V, Matteucci M, Pasanisi EM, et al. Ticagrelor enhances release of anti-hypoxic cardiac progenitor cell-derived exosomes through increasing cell proliferation in vitro. Sci Rep. 2020; 10(1):2494.

[58] Sekhavati N, Noori E, Abbasifard M, Butler AE, Sahebkar A. How statin drugs affect exosomes? J Cell Biochem. 2023; 124(2): 171-180.

[59] Burke M, Waites C. Glucocorticoids regulate small extracellular vesicle (sEV) release via activation of nSMase2. Preprint. bioRxiv. 2025;2025.10.07.680983.

[60] Sandona M, Consalvi S, Tucciarone L, et al. HDAC inhibitors tune miRNAs in extracellular vesicles of dystrophic muscle-resident mesenchymal cells. EMBO Rep. 2020; 21(9):e50863.

[61] Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014; 30: 255-289.

[62] Papini G, Furini G, Matteucci M, et al. Cardiomyocyte-targeting exosomes from sulforaphane-treated fibroblasts affords cardioprotection in infarcted rats. J Transl Med. 2023; 21(1):313.

[63] Xu CM, Broadwin M, Faherty P, et al. Lack of cardiac benefit after intramyocardial or intravenous injection of mesenchymal stem cell-derived extracellular vesicles supports the need for optimized cardiac delivery. Vessel Plus. 2023; 7: 33.

[64] Sahoo S, Losordo DW. Exosomes and cardiac repair after myocardial infarction. Circ Res. 2014; 114(2): 333-344.

[65] Wang S, Wu R, Chen Q, Liu T, Li L. Exosomes derived from TNF-α-treated bone marrow mesenchymal stem cells ameliorate myocardial infarction injury in mice. Organogenesis. 2024; 20(1):2356341.

[66] Kwon J-S, Schumacher SM, Gao E, et al. Characterization of βARKct engineered cellular extracellular vesicles and model specific cardioprotection. Am J Phys Heart Circ Phys. 2021; 320(4): H1276-H1289.

[67] Zhang Y, Cai Z, Shen Y, et al. Hydrogel-load exosomes derived from dendritic cells improve cardiac function via Treg cells and the polarization of macrophages following myocardial infarction. J Nanobiotechnol. 2021; 19(1):271.

[68] Liu X, Li X, Zhu W, et al. Exosomes from mesenchymal stem cells overexpressing MIF enhance myocardial repair. J Cell Physiol. 2020; 235(11): 8010-8022.

[69] Amirzadeh Gougheri K, Ahmadi A, Ahmadabadi MG, et al. Exosomal cargo: pro-angiogeneic, anti-inflammatory, and regenerative effects in ischemic and non-ischemic heart diseases—a comprehensive review. Biomed Pharmacother. 2023; 168:115801.

[70] Czosseck A, Chen MM, Nguyen H, et al. Porous scaffold for mesenchymal cell encapsulation and exosome-based therapy of ischemic diseases. J Control Release. 2022; 352: 879-892.

[71] Smyth T, Kullberg M, Malik N, Smith-Jones P, Graner MW, Anchordoquy TJ. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. J Control Release. 2015; 199: 145-155.

[72] Liam-Or R, Faruqu FN, Walters A, et al. Cellular uptake and in vivo distribution of mesenchymal-stem-cell-derived extracellular vesicles are protein corona dependent. Nat Nanotechnol. 2024; 19(6): 846-855.

[73] Rai A, Claridge B, Lozano J, Greening DW. The discovery of extracellular vesicles and their emergence as a next-generation therapy. Circ Res. 2024; 135(1): 198-221.

[74] Zhang N, Song Y, Huang Z, et al. Monocyte mimics improve mesenchymal stem cell-derived extracellular vesicle homing in a mouse MI/RI model. Biomaterials. 2020; 255:120168.

[75] Liu H, Gao W, Yuan J, et al. Exosomes derived from dendritic cells improve cardiac function via activation of CD4(+) T lymphocytes after myocardial infarction. J Mol Cell Cardiol. 2016; 91: 123-133.

[76] Nahrendorf M, Swirski FK, Aikawa E, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007; 204(12): 3037-3047.

[77] Yao J, Huang K, Zhu D, et al. A minimally invasive exosome spray repairs heart after myocardial infarction. ACS Nano. 2021; 15(7): 11099-11111.

[78] Tzng E, Bayardo N, Yang PC. Current challenges surrounding exosome treatments. Extracell Vesicle. 2023; 2:100023.

[79] Khan M, Nickoloff E, Abramova T, et al. Embryonic stem cell–derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. Circ Res. 2015; 117(1): 52-64.

[80] Kanazawa H, Tseliou E, Dawkins JF, et al. Durable benefits of cellular postconditioning: long-term effects of allogeneic cardiosphere-derived cells infused after reperfusion in pigs with acute myocardial infarction. J Am Heart Assoc. 2016; 5(2):e002796.

[81] Pu Y, Li C, Qi X, et al. Extracellular vesicles from NMN preconditioned mesenchymal stem cells ameliorated myocardial infarction via miR-210-3p promoted angiogenesis. Stem Cell Rev Rep. 2023; 19(4): 1051-1066.

[82] Sun Y, Sun F, Xu W, Qian H. Engineered extracellular vesicles as a targeted delivery platform for precision therapy. Tissue Eng Regener Med. 2023; 20(2): 157-175.

[83] Gowda BHJ, Ahmed MG, Sahebkar A, Riadi Y, Shukla R, Kesharwani P. Stimuli-responsive microneedles as a transdermal drug delivery system: a demand-supply strategy. Biomacromolecules. 2022; 23(4): 1519-1544.

[84] Weinberger F, Breckwoldt K, Pecha S, et al. Cardiac repair in Guinea pigs with human engineered heart tissue from induced pluripotent stem cells. Sci Transl Med. 2016; 8(363):363ra148.

[85] Zhang J, Zhu W, Radisic M, Vunjak-Novakovic G. Can we engineer a human cardiac patch for therapy? Circ Res. 2018; 123(2): 244-265.

[86] Huang K, Hu S, Cheng K. A new era of cardiac cell therapy: opportunities and challenges. Adv Healthc Mater. 2019; 8(2):e1801011.

[87] Cui H, Liu C, Esworthy T, et al. 4D physiologically adaptable cardiac patch: a 4-month in vivo study for the treatment of myocardial infarction. Sci Adv. 2020; 6(26):eabb5067.

[88] Huang K, Ozpinar EW, Su T, et al. An off-the-shelf artificial cardiac patch improves cardiac repair after myocardial infarction in rats and pigs. Sci Transl Med. 2020; 12(538):eaat9683.

[89] Su T, Huang K, Mathews KG, et al. Cardiac stromal cell patch integrated with engineered microvessels improves recovery from myocardial infarction in rats and pigs. ACS Biomater Sci Eng. 2020; 6(11): 6309-6320.

[90] Kang M, Jordan V, Blenkiron C, Chamley LW. Biodistribution of extracellular vesicles following administration into animals: a systematic review. J Extracell Vesicles. 2021; 10(8):e12085.

[91] Wang Y, Qin B, Xia G, Choi SH. FDA's poly (lactic-co-glycolic acid) research program and regulatory outcomes. AAPS J. 2021; 23(4):92.

[92] Lorincz AM, Timar CI, Marosvari KA, et al. Effect of storage on physical and functional properties of extracellular vesicles derived from neutrophilic granulocytes. J Extracell Vesicles. 2014; 3:25465.

[93] Ladhoff J, Fleischer B, Hara Y, Volk HD, Seifert M. Immune privilege of endothelial cells differentiated from endothelial progenitor cells. Cardiovasc Res. 2010; 88(1): 121-129.

[94] Marino J, Babiker-Mohamed MH, Crosby-Bertorini P, et al. Donor exosomes rather than passenger leukocytes initiate alloreactive T cell responses after transplantation. Sci Immunol. 2016; 1(1):aaf8759.

[95] Chen CW, Wang LL, Zaman S, et al. Sustained release of endothelial progenitor cell-derived extracellular vesicles from shear-thinning hydrogels improves angiogenesis and promotes function after myocardial infarction. Cardiovasc Res. 2018; 114(7): 1029-1040.

[96] Chen MH, Chung JJ, Mealy JE, et al. Injectable supramolecular hydrogel/microgel composites for therapeutic delivery. Macromol Biosci. 2019; 19(1):e1800248.

[97] Loebel C, Rodell CB, Chen MH, Burdick JA. Shear-thinning and self-healing hydrogels as injectable therapeutics and for 3D-printing. Nat Protoc. 2017; 12(8): 1521-1541.

[98] Thery C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018; 7(1):1535750.

[99] Zhang YQ, Hong L, Jiang YF, et al. hAECs and their exosomes improve cardiac function after acute myocardial infarction in rats. Aging (Albany NY). 2021; 13(11): 15032-15043.

[100] Ju C, Shen Y, Ma G, et al. Transplantation of cardiac mesenchymal stem cell-derived exosomes promotes repair in ischemic myocardium. J Cardiovasc Transl Res. 2018; 11(5): 420-428.

[101] Besse B, Charrier M, Lapierre V, et al. Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Onco Targets Ther. 2016; 5(4):e1071008.

[102] Serrano DR, Juste F, Anaya BJ, et al. Exosome-based drug delivery: a next-generation platform for cancer, infection, neurological and immunological diseases, gene therapy and regenerative medicine. Pharmaceutics. 2025; 17(10): 1336.

[103] Luo W, Li H, Zhang P, et al. Apoptotic bodies derived from human umbilical cord mesenchymal stem cells improve recovery from myocardial infarction in swine. Autophagy. 2026; 22(3): 603-622.

[104] Hu XM, Wang CC, Xiao Y, et al. Non-clinical safety evaluation of exosomes derived from human umbilical cord mesenchymal stem cells in cynomolgus monkeys. Int J Nanomedicine. 2024; 19: 4923-4939.

[105] Welsh JA, Goberdhan DCI, O'Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches. J Extracell Vesicles. 2024; 13(2):e12404.

[106] Patel DB, Gray KM, Santharam Y, Lamichhane TN, Stroka KM, Jay SM. Impact of cell culture parameters on production and vascularization bioactivity of mesenchymal stem cell-derived extracellular vesicles. Bioeng Transl Med. 2017; 2(2): 170-179.

[107] Labusek N, Mouloud Y, Koster C, et al. Extracellular vesicles from immortalized mesenchymal stromal cells protect against neonatal hypoxic-ischemic brain injury. Inflamm Regen. 2023; 43(1):24.

[108] Penna C, Femmino S, Alloatti G, Brizzi MF, Angelone T, Pagliaro P. Extracellular vesicles in comorbidities associated with Ischaemic heart disease: focus on sex, an overlooked factor. J Clin Med. 2021; 10(2):327.

[109] Schena GJ, Murray EK, Hildebrand AN, et al. Cortical bone stem cell-derived exosomes' therapeutic effect on myocardial ischemia-reperfusion and cardiac remodeling. Am J Physiol Heart Circ Physiol. 2021; 321(6): H1014-H1029.

[110] Pan J, Alimujiang M, Chen Q, Shi H, Luo X. Exosomes derived from miR-146a-modified adipose-derived stem cells attenuate acute myocardial infarction-induced myocardial damage via downregulation of early growth response factor 1. J Cell Biochem. 2019; 120(3): 4433-4443.

[111] Zhang Z, Yang J, Yan W, Li Y, Shen Z, Asahara T. Pretreatment of cardiac stem cells with exosomes derived from mesenchymal stem cells enhances myocardial repair. J Am Heart Assoc. 2016; 5(1):e002856.

[112] Huang P, Wang L, Li Q, et al. Combinatorial treatment of acute myocardial infarction using stem cells and their derived exosomes resulted in improved heart performance. Stem Cell Res Ther. 2019; 10(1):300.

[113] Liu L, Jin X, Hu CF, Li R, Zhou Z, Shen CX. Exosomes derived from mesenchymal stem cells rescue myocardial ischaemia/reperfusion injury by inducing cardiomyocyte autophagy via AMPK and Akt pathways. Cell Physiol Biochem. 2017; 43(1): 52-68.

[114] Chen Q, Huang M, Wu J, Jiang Q, Zheng X. Exosomes isolated from the plasma of remote ischemic conditioning rats improved cardiac function and angiogenesis after myocardial infarction through targeting Hsp70. Aging (Albany NY). 2020; 12(4): 3682-3693.

[115] Johnson TK, Zhao L, Zhu D, et al. Exosomes derived from induced vascular progenitor cells promote angiogenesis in vitro and in an in vivo rat hindlimb ischemia model. Am J Phys Heart Circ Phys. 2019; 317(4): H765-H776.

RIGHTS & PERMISSIONS

2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.